pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Antibody-Drug Conjugate (ADC) · news · pharmadog
← back to Antibody-Drug Conjugate (ADC)
News · Antibody-Drug Conjugate (ADC)
131
stories
1d
Out of sight, out of work? What’s driving remote job cuts
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
6d
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
endpoints
15d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
17d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
17d
Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E
endpoints
17d
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
21d
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
22d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
22d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
23d
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
24d
GSK partner Hansoh reports another phase 3 win for priority ADC
fiercebiotech
24d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
24d
Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
endpoints
25d
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
28d
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
biospace
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 21, 26
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
fiercebiotech
Jul 16, 26
Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer's Hernexeos
endpoints
Jul 16, 26
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
biospace
Jul 15, 26
Merck ADC, in China study, shows potential to replace chemo in lung cancer
biopharma dive
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jul 10, 26
GSK, Hansoh ADC extends survival in lung cancer study
biopharma dive
Jul 10, 26
Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
endpoints
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jul 6, 26
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
endpoints
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
← prev
page 1 of 5
next →
